8 Best Stem Cell Therapy Clinics in US and the World 2026

By Dr. Frank Yap, MD · OneDayMD Network · Last reviewed and updated: November 15, 2026 · Originally published June 2022

Quick answer

No stem cell clinic is “FDA-approved.” The FDA licenses products, not clinics, and the only stem-cell-based products it has approved are for specific blood and immune conditions: cord blood products, Omisirge, and, since December 2024, Ryoncil, the first mesenchymal stromal cell therapy (for pediatric steroid-refractory acute graft-versus-host disease).

The providers below mostly market other uses (joint pain, multiple sclerosis, heart failure, autoimmune disease, “anti-aging”) for which no stem cell product is approved. We profile them so readers can research them, not as recommendations. For most, the best public evidence we could find is uncontrolled (CEBM Level 4–5).

Laboratory illustration for a guide to stem cell therapy clinics and centers

This guide profiles eight stem cell centers, clinics and research groups that readers often ask about, plus one provider whose current status we could not confirm. It was first published in 2022 and fully re-audited on November 15, 2026. Each entry separates what the organization says about itself from what independent sources document, and assigns an evidence tier to the best public evidence we located. Inclusion is not an endorsement or a recommendation to seek treatment.

Medical disclaimer

This article is educational and is not medical advice. Stem cell products used outside FDA-approved indications or registered trials carry risks, including infection, unwanted tissue growth and no benefit at all. Discuss any treatment with a physician who is independent of the provider selling it.

What “FDA-approved” does and does not mean

The FDA licenses specific biological products for specific uses. The agency’s approved cellular and gene therapy products list includes multiple cord blood–derived blood-forming progenitor cell products, Omisirge (cord blood–derived cells for patients with blood cancers undergoing cord blood transplantation) and Ryoncil (remestemcel-L), approved on December 18, 2024 for steroid-refractory acute graft-versus-host disease in children aged two months and older.

Enforcement against unproven clinics is continuing. In a September 2026 STAT column, UC Davis stem cell biologist Paul Knoepfler wrote that the FDA’s biologics center has kept taking action against clinics selling unapproved products, and cited an estimate of more than 2,000 such firms in the US, drawn from a peer-reviewed count of clinics conducted a few years earlier.

Words that are not “FDA-approved”
  • FDA-registered facility: the establishment filed a registration. It says nothing about whether its products work.
  • IRB-approved protocol: an ethics board reviewed participant protections. It is not evidence of efficacy.
  • Licensed offshore: a foreign jurisdiction permits the clinic to operate.
  • Expanded access (“compassionate use”): individual-patient access to an investigational product. It is not a finding that the therapy works.

How we tier the evidence (CEBM)

We assign each provider a tier based on the best public evidence we located for its headline claims, using the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy. These are editorial assessments as of November 15, 2026, not regulatory findings, and a provider could hold stronger unpublished data.

CEBM tier What it means Typical examples here
Level 1 Systematic review of randomized controlled trials None of the clinic-specific claims below reach this tier
Level 2 Individual randomized trial or well-followed cohort None located for the clinic-specific claims below
Level 3 Non-randomized controlled study None located
Level 4 Case series, uncontrolled study or registry Panama MS study; Regenexx registry; GIOSTAR COVID-19 series
Level 5 Mechanistic reasoning, preclinical or lab work, expert opinion, or company statements HI-STEM lab research; marketing claims from DVC Stem, Celltex, QC Kinetix, Stem Cell Malaysia

Providers at a glance

Provider Base What it markets Best public evidence located Tier Main flag
GIOSTAR Chicago area; sites in Mexico, India, Brazil, Thailand, UAE (company-stated) Joint, lung, autoimmune, aesthetic and post-COVID uses Company-reported 7-patient COVID-19 series; Phase 2 IND for type 2 diabetes cleared Nov 2024 (no results located) 4 Expanded access is not trial approval; 2019 credential questions
Stem Cell Institute Panama City, Panama MS, spinal cord injury, RA, heart failure, OA, autism, CP 20-patient open-label, single-arm MS study (2018) 4 Sponsor-affiliated authors; no control group
HI-STEM Heidelberg, Germany Research institute (leukemic and cancer stem cells) Laboratory and translational research 5 Not a treatment clinic
Regenexx Colorado; physician network; Cayman Islands site Orthopedic bone marrow and blood-derived procedures; culture-expanded cells offshore Industry-sponsored observational registry 4 Culture-expanded cells are drugs under FDA rules; registry has no control group
DVC Stem Grand Cayman IV cord-tissue MSCs for many conditions Company-stated IRB protocol; no peer-reviewed efficacy data surfaced 5 Broad condition list; high price per independent commentary
Celltex Houston, Texas; infusions historically in Mexico Fat-derived MSC banking and later infusion None located 5 2012 FDA inspection findings; current model unverified
QC Kinetix US franchise network PRP and bone marrow concentrate injections for joint pain None located for stem-cell claims 5 Class-action allegations; shrinking network
Stem Cell Malaysia Kuala Lumpur Individualized stem cell therapy (allogeneic or autologous) Company statements only 5 Published by this site; NPRA context

The providers, one by one

1. GIOSTAR (Global Institute of Stem Cell Therapy and Research) CEBM Level 4

GIOSTAR markets autologous and allogeneic adult stem cell treatments for joint pain, orthopedic injuries, arthritis, lung disease, hair loss, erectile dysfunction, autoimmune disease and post-COVID complications, plus anti-aging and aesthetic services such as IV vitamin therapy. It says it treats patients at a Chicago-area clinic and at sites in Mexico, India, Brazil, Thailand and the UAE. These are company statements; we could not independently verify clinic licensing.

What is documented:

  • May 2020: GIOSTAR announced FDA authorization to treat COVID-19 patients under expanded access (“compassionate use”), case by case. It also reported that seven COVID-19 patients recovered after IV allogeneic mesenchymal stem cells, in a study published in Aging and Disease (trade-press summary); that is a very small uncontrolled series.
  • November 2024: the company announced FDA clearance of an IND to begin a Phase 2 trial of a cell therapy for type 2 diabetes. In a November 2024 commentary, Paul Knoepfler said he could not find a ClinicalTrials.gov listing or published results for the program and questioned its scientific rationale.
  • January 2019: a Los Angeles Times investigation reported that institutions named in the founder’s biography disputed some claimed affiliations, and noted that the FDA had taken no action against GIOSTAR at that time. We did not locate a published GIOSTAR rebuttal in our review.

Correction to the 2022 version: the earlier text said GIOSTAR had been “working with the FDA on clinical trials” for COVID-19. The documented pathway was expanded access, which is not the same thing.

2. Stem Cell Institute (Panama City, Panama) CEBM Level 4

Founded by Neil Riordan, PhD, the Stem Cell Institute offers allogeneic umbilical cord mesenchymal stem cell protocols and autologous bone marrow cell protocols. It markets them for conditions including spinal cord injury, rheumatoid arthritis, heart failure, osteoarthritis, multiple sclerosis, autoimmune disease, autism and cerebral palsy. No stem cell product is FDA-approved for any of these indications.

The multiple sclerosis study, read carefully. The clinic’s best-known paper (Riordan et al., J Transl Med 2018; registry NCT02034188) gave 20 people with MS seven IV infusions of umbilical cord MSCs over seven days. It was an open-label, single-arm, single-center phase 1/2 study with no control group. No serious adverse events were reported, symptom improvements were most notable at one month, and MRI showed inactive lesions in 15 of 18 participants at one year. A published correction clarified that the sponsor had a role in the study’s design and that an author is a shareholder of the sponsor and the clinic.

What this design can and cannot show

A small uncontrolled study can show feasibility and short-term safety. It cannot show that the treatment slows MS, and it cannot show that it outperforms disease-modifying drugs. The 2022 version of this page described the cells as a “safe and effective” approach with “more durable benefits than current MS drug therapies”; the paper does not support that conclusion, so we removed it.

We also removed the embedded social media post and celebrity testimonial links that appeared here previously: they are marketing, not clinical evidence.

3. HI-STEM: Heidelberg Institute for Stem Cell Technology and Experimental Medicine CEBM Level 5

HI-STEM gGmbH is a non-profit public–private partnership between the German Cancer Research Center (DKFZ) in Heidelberg and the Dietmar Hopp Foundation, founded in 2008 and directed by Prof. Andreas Trumpp. It studies normal and malignant stem cells, with emphasis on blood-forming and leukemic stem cells and on cancer progression and metastasis, and aims to turn findings into diagnostics and therapies. See its research topics page for current groups.

Important: a research institute, not a clinic

HI-STEM appears here because readers search for it, but it is a laboratory and translational research organization. Patients seeking treatment in Germany should speak with the university hospitals in Heidelberg and Mannheim or the National Center for Tumor Diseases (NCT), with which HI-STEM collaborates. Laboratory findings are CEBM Level 5 for any patient-care question.

4. Regenexx CEBM Level 4

Colorado-based Regenexx, founded by Christopher Centeno, MD, offers same-day procedures that use a patient’s own bone marrow and blood, processed and injected during one visit, mainly for orthopedic conditions. It licenses these procedures to a network of physicians across the US. For larger cell numbers it offers laboratory-expanded (“culture-expanded”) cells at a licensed clinic in Grand Cayman.

  • Regulatory line: the FDA treats culture-expanded cells as drugs that need approval, which is why Regenexx offers them offshore (a point the company itself makes). US patients who travel for them are leaving the FDA framework.
  • Registry: Regenexx sponsors an observational orthobiologics outcomes registry (NCT03011398) that follows patients at 1, 3, 6, 12 and 18 months and then annually for up to 20 years; its listing was last updated in April 2025. A sponsor-run registry without a control group cannot separate treatment effect from natural recovery or placebo response, so we rate it Level 4.
  • Cost: Regenexx states that most insurance plans do not cover its procedures.

We removed the 2022 sentence about a named patient testimonial, which was fused to a biography line and read as an error.

5. DVC Stem (Grand Cayman) CEBM Level 5

DVC Stem says it has operated in Grand Cayman since 2009 under Medical Director Louis A. Cona, MD. It markets IV cord tissue–derived mesenchymal stem cells for conditions that include multiple sclerosis, Parkinson’s disease, osteoarthritis, stroke and spinal cord injury. Its cells come from Vitro Biopharma in Colorado, which the clinic describes as FDA-registered, cGMP-compliant and ISO-certified, and its protocol is described as a two-day infusion of 300 million culture-expanded allogeneic cells.

  • Company-stated safeguards: an IRB-approved protocol (US board), a study registered with the Cayman Islands government, and Cayman licensing. We could not independently verify these.
  • What they do not establish: an FDA-registered laboratory is not an FDA-approved product, and IRB approval is not evidence of efficacy. No peer-reviewed efficacy results for the clinic surfaced in our review.
  • Independent commentary: Paul Knoepfler has criticized DVC’s promotion of unproven treatments for conditions such as COPD and noted a price point near $25,000.

We removed the list of named celebrity patients that appeared in the earlier version.

6. Celltex (Houston, Texas) CEBM Level 5

Celltex banks mesenchymal stem cells grown from a small sample of a patient’s fat tissue, which a licensed physician can later infuse or inject. Because expanded cells are regulated as drugs in the US, Celltex has historically delivered infusions through physicians abroad.

  • Regulatory history: a 2012 FDA inspection of its cell bank reportedly recorded 79 deficiencies, and the company then moved patient treatments to Mexico. Texas later passed a state law permitting certain non-FDA-approved stem cell treatments; the FDA has said state law is subordinate to federal rules (The Scientist).
  • Trials: the earlier text said Celltex had begun the process of running clinical trials. Check any such claim against ClinicalTrials.gov before relying on it.
  • Status: these sources are several years old and we could not confirm Celltex’s current service model for this update. Verify directly before relying on this entry.

7. QC Kinetix (US franchise network) CEBM Level 5

QC Kinetix is a franchise network offering regenerative injections, mainly platelet-rich plasma (PRP) and bone marrow concentrate, for knee, shoulder, elbow and other joint pain. It has reported more than 100 clinic locations; trade press describes closures, some of them framed by the company as strategic.

  • Litigation (allegations only): a 2023 Illinois consumer-fraud suit (Robertson) and a proposed class action filed in March 2026 on behalf of Florida patients (Estrada et al. v. QC Franchise Group LLC et al.) allege that patients were not told the treatments lack FDA approval. The company has said its treatments are not required to be FDA-approved.
  • Independent view: Paul Knoepfler’s review said he sees no good evidence for the brand’s claims, while noting that PRP and unmodified bone marrow for orthopedic uses are generally viewed as FDA-compliant. PRP evidence for some joint conditions is a separate question from “stem cell” marketing.
  • Our tier: Level 5 for the stem cell claims specifically.

We removed the 2022 promotional line describing QC Kinetix as “the place to go” for patients told they need surgery.

8. Stem Cell Malaysia (SCM) CEBM Level 5

Disclosure

Stem Cell Malaysia is published and promoted on this website (stemcell.aestheticsadvisor.com). It is not an independent listing. We apply the same evidence tier we use for other providers whose claims are company-stated, and no published outcome data are cited on this page.

The Malaysian Stem Cell Therapy Working Group (“Stem Cell Malaysia”) describes itself as a network of multidisciplinary doctors, established in 2017, offering regenerative, integrative and lifestyle medicine and assisting international patients. It says it operates through Gleneagles Hospital Kuala Lumpur as its main partner medical center and that each person is assessed and pre-qualified for an individualized recommendation, using allogeneic or autologous cells. These are company statements.

For regulatory context see the Malaysia section below. Questions about regional options: WhatsApp +60 11-1156 7369. Consultations are informational and do not guarantee treatment eligibility or outcomes.

Previously listed: Okyanos (Freeport, Bahamas), status unconfirmed

Check before relying on this listing

Okyanos was a licensed Bahamian provider of fat-derived cell therapy (including for heart failure). Bahamian press reported that it remained closed after Hurricane Dorian in 2019 and later entered Supreme Court-supervised liquidation proceedings in 2020. Business databases conflict on its status: some list it as defunct, others as active. We could not confirm that treatments are currently offered, so we removed it from the featured list. If it is operating, confirm its Bahamas National Stem Cell Ethics Committee licence directly.

Market-size figures: why they disagree

Earlier versions of this article quoted a single stem cell therapy market estimate. Current analyst figures differ by roughly 40-fold depending on what each firm counts (therapy sales alone versus research tools, banking and regenerative medicine broadly). Treat all of them as directional vendor estimates, not clinical evidence.

Publisher Scope Estimate
Towards Healthcare Stem cell therapy $613.7 million (2025); $768.7 million (2026)
Knowledge Sourcing Intelligence Stem cell therapy $392.5 million (2025)
MarketsandMarkets Stem cell therapy $0.48 billion (2026)
BCC Research Stem cell and regenerative therapy (broad) $16.7 billion (2025), projected $43.8 billion by 2030

Regional note: Malaysia

Malaysia regulates cell and gene therapy products through the National Pharmaceutical Regulatory Agency (NPRA). Mandatory registration of higher-risk products began on January 1, 2021, and a second edition of the NPRA guidance took effect in September 2025. As of December 2025, the Malaysia Healthcare Travel Council stated that no stem cell or cell-based product had been approved or registered by NPRA as a medicinal product for routine clinical use. Ministry of Health guidelines and ethics review also apply to stem cell research and therapy.

Practical step: ask any Malaysian provider which pathway covers the exact product you would receive, and request the registration or ethics approval number in writing.

Questions to ask and red flags

Ask before any procedure

  1. Regulatory status: Is this exact product FDA-approved (or NPRA-registered) for my condition? If not, under which trial or approval pathway is it given? What is the registration number?
  2. Evidence: Where are the published results for my condition, including patients who did not improve? Is there a control group?
  3. Source and processing: Where do the cells come from, who manufactures them, and how are sterility and identity tested?
  4. Safety: What adverse events have occurred, how are they recorded, and who treats a complication after I return home?
  5. Alternatives: What approved treatments or registered trials exist for my condition?
  6. Cost and rights: What is the total itemized price, including travel and repeat doses? What is the refund, compensation and withdrawal policy?
  7. The clinician: Who performs the procedure, what are their credentials and licences, and do they have a financial stake in the clinic?

Red flags

Walk away or slow down if you see
  • Claims that the clinic is “FDA-approved” or “FDA-compliant” with no product approval to show
  • One product marketed for many unrelated diseases, including autism, cerebral palsy or “anti-aging”
  • Testimonials or celebrity endorsements offered in place of data
  • Guaranteed or dramatic outcomes; pressure to pay or finance on the spot
  • No trial registration number, or no willingness to share adverse-event information

AI personalization guide

AI assistants can help you stress-test a clinic’s claims, but they cannot verify a licence or a registration number. Use them to organize questions, then confirm every fact at the regulator or registry itself.

Assistant Good for Prompt to try
Claude Reading a clinic page critically and mapping claims to evidence “Here is a clinic’s treatment page [paste]. List every medical claim, say whether an FDA-approved product exists for that indication, and tell me what evidence would be needed to support it.”
ChatGPT Drafting consultation questions and plain-language summaries of documents you upload “Draft 10 questions for my first consult about regulatory status, adverse-event reporting, total cost and complication care for [treatment] for [my condition].”
Gemini Cross-checking names, locations and dates across the web “Find news coverage, court filings and regulator notices about [clinic] and list the date and source of each. Say what you could not find.”
Perplexity Citation-first searching of registries and papers “Search ClinicalTrials.gov and PubMed for [clinic/product] in [condition]. Give links, trial status and whether results are posted.”

Frequently asked questions

Is there such a thing as an FDA-approved stem cell clinic?

No. The FDA approves specific products for specific uses; it does not approve or certify clinics, and no list of FDA-approved stem cell clinics exists. A clinic can legally use an FDA-approved product for its approved use or run a trial under an FDA-cleared IND. Terms such as FDA-registered, FDA-compliant or IRB-approved are not the same as FDA-approved: they describe a facility registration or an ethics review, not proof that a treatment works.

Which stem cell treatments are actually FDA-approved?

The FDA list of approved cellular and gene therapy products includes cord blood-derived blood-forming (hematopoietic) progenitor cell products, Omisirge for certain blood cancer patients undergoing cord blood transplantation, and Ryoncil (remestemcel-L), approved in December 2024 as the first mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in children aged two months and older. No stem cell product is FDA-approved for osteoarthritis, multiple sclerosis, heart failure, autism, cerebral palsy or anti-aging.

Do offshore clinics have better evidence than US clinics?

Not by virtue of location. A licence from a foreign government or an ethics committee allows a clinic to operate; it does not show that a treatment works. Offshore operators can also close or change hands: Bahamian press reported that Okyanos, once a prominent Freeport provider, closed after Hurricane Dorian in 2019 and entered court-supervised liquidation proceedings in 2020.

Are umbilical cord stem cells proven for multiple sclerosis?

No. Cord-derived mesenchymal stem cell infusions for MS remain investigational. The best-known published study, from the Stem Cell Institute in Panama, enrolled 20 people in an open-label, single-arm design with no control group and a sponsor-affiliated author team, so it can speak to feasibility and short-term safety but not to effectiveness. Hematopoietic stem cell transplantation for highly active relapsing MS is a different procedure, done in transplant centers, with randomized trial data in selected patients.

Is stem cell therapy approved in Malaysia?

Malaysia regulates cell and gene therapy products through the National Pharmaceutical Regulatory Agency (NPRA), with mandatory registration of higher-risk products beginning on January 1, 2021. As of December 2025 the Malaysia Healthcare Travel Council stated that no stem cell or cell-based product had been approved or registered by NPRA for routine clinical use. Ask any provider which regulatory pathway (NPRA registration or ethics-approved research) covers the exact product you would receive, and request the registration or approval number in writing.

How much do clinic stem cell treatments cost?

There is no standard price. Unproven treatments are usually self-pay, and insurers generally do not cover them; Regenexx, for example, states that most insurance plans do not cover its procedures. Third-party directories list price ranges that we could not verify, so we do not publish them. Ask for an itemized written quote that includes travel, repeat treatments and the cost of managing complications.

What are the biggest red flags when choosing a stem cell clinic?

Claims that the clinic itself is FDA-approved; one product marketed for many unrelated diseases; patient testimonials or celebrity endorsements offered in place of data; guaranteed or dramatic outcomes; pressure to pay or finance quickly; no trial registration number; and reluctance to share adverse-event information or the treating physician's credentials.

How can I check a clinic's trial or regulatory claims?

Search the registration number on ClinicalTrials.gov and confirm the sponsor, phase, status and whether results have been posted. Search the clinic and its principals in the FDA warning letter database and in court records. For Malaysia, check NPRA product registration; for offshore clinics, check the local health regulator. If a clinic cannot give you a registration or approval number, treat the treatment as unregistered.

Disclosures

Commercial and editorial disclosures
  • Stem Cell Malaysia, profiled above, is published and promoted on this website.
  • The OneDayMD network participates in affiliate programs, including Amazon Associates and The Wellness Company. This article contains no affiliate links; the related-reading link to our supplements guide may lead to pages that do.
  • Inclusion in this guide is not an endorsement. Any commercial relationship with a profiled provider is disclosed in that provider’s entry.
  • Some original 2022 clinic descriptions were adapted from BioInformant, which carries sponsored content for some clinics. We rewrote and re-verified each entry for this update.

Sources and update log

  1. FDA: Approved Cellular and Gene Therapy Products
  2. REPROCELL: FDA stem cell approvals 2023–2025 (Ryoncil approval, December 18, 2024)
  3. STAT, Knoepfler: FDA and unproven stem cell clinics (September 3, 2026)
  4. Riordan et al., J Transl Med 2018;16:57 (MS feasibility study) and its correction
  5. Regenexx orthobiologics registry (NCT03011398)
  6. GIOSTAR expanded-access announcement (May 2020); GIOSTAR IND clearance (November 2024); Knoepfler commentary (November 2024); Los Angeles Times (January 2019)
  7. Knoepfler on DVC Stem; Knoepfler on QC Kinetix; Estrada v. QC Franchise Group (filed March 2026); Franchise Times on QC Kinetix
  8. Tribune242: Okyanos after Hurricane Dorian (2019); Tribune242: Okyanos liquidation (2020)
  9. Nature News blog: FDA audit of Celltex (2012); The Scientist: Celltex moves to Mexico; The Scientist: Texas stem cell law
  10. Malaysia Healthcare Travel Council (December 2025); NPRA CGTP guidance, 2nd edition (September 2025); Regulatory oversight of CGTPs in Malaysia

Update log (November 15, 2026):

  • Replaced the “safe and effective” MS claim with the Panama study’s actual design and limitations.
  • Corrected GIOSTAR’s COVID-19 status (expanded access) and added its November 2024 IND.
  • Reclassified HI-STEM as a research institute and removed outdated staff listings.
  • Moved Okyanos to a status-check note; added Celltex and QC Kinetix regulatory and legal context.
  • Removed celebrity endorsements, an embedded social post and named-patient testimonials.
  • Replaced a single market estimate with a range; added the Malaysia regulatory section, CEBM tiers, FAQ and disclosures.

More questions? Contact us.

Comments

Popular posts from this blog

Top Companies in CAR T-cell Therapy (2026)

Top Exosome Companies Worldwide 2025